نتایج جستجو برای: cholinesterase inhibitors

تعداد نتایج: 191405  

Journal: :Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2011
Miroslav Pohanka

BACKGROUND Cholinesterases are a group of serine hydrolases that split the neurotransmitter acetylcholine (ACh) and terminate its action. Of the two types, butyrylcholinesterase and acetylcholinesterase (AChE), AChE plays the key role in ending cholinergic neurotransmission. Cholinesterase inhibitors are substances, either natural or man-made that interfere with the break-down of ACh and prolon...

Journal: :genetics in the 3rd millennium 0
مازیار سیدیان maziar seyedian tehran university of medical sciences, tehran, iranاستاد یار نورولوژی، دانشگاه علوم پزشکی تهران، تهران، ایران

alzheimers disease (ad) is by far the most common cause of dementia. definite diagnosis of ad is based on pathological findings. nincds-adrda criteria, published more than 25 years ago, are commonly used for the clinical diagnosis of ad. however, considering serious shortcomings of these criteria, new criteria have been proposed. according to these new criteria, ad can be diagnosed in predement...

Journal: :Journal of The Serbian Chemical Society 2023

In search of potent inhibitors cholinesterase enzymes and antioxidant agents, synthetic derivatives dihydroquinazolin-4(1H)-one 1-38 were evaluated as potential anti-Alzheimer agents through in vitro acetylcholinesterase (AChE) butyrylcholinesterase (BChE) inhibitions radical (DPPH ABTS) scavenging activities. The (SAR) was mainly based on the different substituents at aryl part which showed a ...

2013
Nicole R Fowler Yi-Fan Chen Christiana A Thurton Aiju Men Eric G Rodriguez Julie M Donohue

BACKGROUND Cholinesterase inhibitors and memantine are prescribed to slow the progression dementia. Although the efficacy of these drugs has been demonstrated, their effectiveness, from the perspective of patients and caregivers, has been questioned. Little is known about whether the demand for cholinesterase inhibitors and memantine are sensitive to out-of-pocket cost. Using the 2006 implement...

Journal: :Trials 2009
Rob Jones Bart Sheehan Patrick Phillips Ed Juszczak Jessica Adams Ashley Baldwin Clive Ballard Sube Banerjee Bob Barber Peter Bentham Richard Brown Alistair Burns Tom Dening David Findlay Richard Gray Mary Griffin Clive Holmes Alan Hughes Robin Jacoby Tony Johnson Roy Jones Martin Knapp James Lindesay Ian McKeith Rupert McShane Ajay Macharouthu John O'Brien Caroline Onions Peter Passmore James Raftery Craig Ritchie Rob Howard

BACKGROUND Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by th...

Journal: :BMC Geriatrics 2007
Udaya P Gammanpila Alistair Burns Richard F Heller Nitin Purandare

BACKGROUND The study aims to quantify the population impact of prescribing cholinesterase inhibitors to slow the cognitive decline in Alzheimer's disease (AD), and to compare with the benefit of treating hypertension to prevent the onset of AD. METHODS Literature review to ascertain the prevalence of AD, benefits of interventions, analysis of local and national surveys to measure the current ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید